ReGenTree announced that the company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at the ARVO meeting. The study was conducted by Jaewook Yang, MD, at the T2B Infrastructure Center for Ocular Disease, InJe University Busan Paik Hospital in Korea. Gabriel Sosne, MD, at Wayne State University School of Medicine, and Hynda Kleinman, PhD, at The George Washington University School of Medicine were among the authors of the study.
ReGenTree’s phase 3 clinical program includes two completed studies in dry eye syndrome that demonstrated positive clinical results for signs and symptoms of dry eye within the RGN-259 group compared to placebo and an ongoing study in patients with chronic neurotrophic keratopathy, an orphan indication. RGN-259 has also demonstrated a strong safety profile with fewer side effects compared to approved products currently on the market.